Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04793659 · ClinicalTrials.gov registry record · Phase 2
Fasudil fOr redUcing elopemeNt and Spatial Disorientation
A Phase 2 study, sponsored by Woolsey Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
NCT04793659 is a Phase 2 study that has completed, run by Woolsey Pharmaceuticals. The registered enrollment target is 24 participants.
The verdict
NCT04793659, a Phase 2 study, has completed, sponsored by Woolsey Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
Study Summary
Fasudil, a Rho kinase inhibitor, is believed to reduce wandering behaviors of elopement and getting lost by improving spatial memory and navigation through improvements in hippocampal blood flow. Fasudil is non-sedating. The aim of the study is to assess the effectiveness of oral fasudil in reducing wandering behaviors of elopement and/or getting lost in subjects with dementia. In addition, effects on wandering behaviors of excess movement and pacing, cognition, memory, neuropsychiatric symptomatology, caregiver/nursing staff burden, and the safety and tolerability of fasudil treatment will be assessed.
Interventions
- DRUG Oral Placebo
- DRUG Oral Fasudil 90 mg/day
- DRUG Oral Fasudil 180 mg/day
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2020-12-15 |
| Est. Completion | 2022-02-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04793659
The ClinicalTrials.gov registry entry for NCT04793659 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Woolsey Pharmaceuticals, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Oral Placebo is the first listed.
NCT04793659 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04793659 about?
NCT04793659 is a clinical study titled "Fasudil fOr redUcing elopemeNt and Spatial Disorientation". Fasudil, a Rho kinase inhibitor, is believed to reduce wandering behaviors of elopement and getting lost by improving spatial memory and navigation through improvements in hippocampal blood flow. Fasudil is non-sedating. The aim of the study is to assess the effectiveness of oral fasudil in reducin...
What is the current status of trial NCT04793659?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2020-12-15. Estimated completion is 2022-02-11.
What interventions are being tested in trial NCT04793659?
The interventions under investigation include: Oral Placebo (DRUG), Oral Fasudil 90 mg/day (DRUG), Oral Fasudil 180 mg/day (DRUG).
Who is sponsoring clinical trial NCT04793659?
This trial is sponsored by Woolsey Pharmaceuticals, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.